“We’ve found that this combination of targeted treatments is both more effective and less toxic than the previous standard of care for these patients. It seems likely that, in the future, these patients will be able to forego chemotherapy altogether.” The study randomized a...
Recently, several new agents have been investigated and have shown promise in treating patients with CLL. These treatments include new mAbs, agents targeting the antiapoptotic bcl-2 family of proteins and receptors involved in mediating survival signals from the microenvironment, antisense oligonucleotides...
Right now, the agents that are approved for CLL in the relapsed/refractory setting are ibrutinib for patients who didn't get it in the frontline setting, idelalisib (Zydelig) if they had more than 2 prior lines or are not eligible for other treatments, and venetoclax (Venclexta) is the m...
BCL-2 and BTK inhibitors for chronic lymphocytic leukemia: current treatments and overcoming resistanceBTK inhibitorsBTK degradersBCL2 inhibitorscellular therapiesCLLPI3k inhibitorsrefractoryrelapsedIntroductionIn the last decade, BTK inhibitors and the BCL-2 inhibitor venetoclax have replaced immunochemotherapy ...
Schistosomiasis, a parasitic disease caused bySchistosomaspecies, affects millions of people worldwide. This review explores the therapeutic challenges of schistosomiasis, focusing on the mechanisms of action of current treatments and their limitations. Praziquantel, the standard therapy, induces lesions and...
These spores have entered phase 1 clinical trials-alone or in combination with chemotherapeutic drugs-for the treatment of solid tumours that are not responding to conventional treatments [82]. When it comes to the fate of the tumour cells under self-regression, apoptosis could be the prevalent ...
MAbs tested to date kill MM cells via the host's immune system and/or by promoting apoptosis, and appear to have generally improved tolerability compared with currently available treatments. Due to their distinct mode of action, mAbs are promising both for patients who have exhausted current ...
Subsets of AML require thoughtful selection of treatments. Figure1A, B shows the outcomes in de novo AML (excluding APL and CBF AML) at MD Anderson from 1980 to 2023 by age among patients treated on protocol therapies. There has been a steady improvement in survival over the decades, more ...
treatments still had an inexorable loss of brain volume. Thus, atrophy persisted even with a lack of relapses [4]. Short of a cure for MS, there remains a critical need for treatments that reduce both symptoms and progression. To find such treatments, targets are required and to find the...
Access to genetic testing and specialized cancer care for individuals at risk of or diagnosed with LFS varies widely by region and healthcare system [198]. In some areas, the availability of genetic testing, surveillance, and specialized treatments may be limited, creating disparities in patient ou...